The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA. - Abstract - Europe PMC
Venetoclax (ABT-199) | BCL-2 Inhibitor | MedChemExpress
An Unexpected Halt in Multiple Myeloma for Venetoclax | Science | AAAS
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Nature Medicine
Navitoclax - an overview | ScienceDirect Topics
Functional evaluation of Bcl2 and BAX mutations. (A) ABT-199 was unable... | Download Scientific Diagram
Venetoclax - Wikipedia
ABT-199 activates the intrinsic mitochondrial apoptosis pathway in... | Download Scientific Diagram
Practical Fragments: Second fragment-based drug approved
Attacking cancer's Achilles heel: antagonism of anti‐apoptotic BCL‐2 family members - Opferman - 2016 - The FEBS Journal - Wiley Online Library
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Nature Medicine
Ibr-7 synergized with ABT-199 in NSCLC A549 cells by triggering... | Download Scientific Diagram
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development | Journal of Hematology & Oncology | Full Text
Cancers | Free Full-Text | Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models | HTML
Identification of tivantinib and ABT-199 as a synergistic drug... | Download Scientific Diagram
Venetoclax (ABT-199): a Selective Inhibitor of B-Cell Lymphoma-2 | Personalized Medicine in Oncology
Frontiers | The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
![PDF] Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0ec51f354d5a228645aef51832a6d296b927bd6b/7-Figure4-1.png "PDF] Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Semantic Scholar")
PDF] Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Semantic Scholar
Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia | Cell Death & Disease
ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca2+‐signalling dysregulation or toxicity in pancreatic acinar cells - Jakubowska - 2019 - British Journal of Pharmacology - Wiley Online Library
ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca2+‐signalling dysregulation or toxicity in pancreatic acinar cells - Jakubowska - 2019 - British Journal of Pharmacology - Wiley Online Library
Updated Results of a Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia | Research To Practice
Imaging Cellular Distribution of Bcl Inhibitors Using Small Molecule Drug Conjugates
